Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
Department of Surgery, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Ann Surg Oncol. 2018 Oct;25(10):2846-2851. doi: 10.1245/s10434-018-6605-4. Epub 2018 Jun 26.
The management of isolated in-breast tumor recurrence is complex, requiring careful consideration of prior local therapies to plan future multimodality treatment. Options for surgical management have evolved from standard salvage mastectomy with axillary clearance and now include repeat breast conservation with axillary staging in select patients. Reattempting sentinel lymph node biopsy may avoid the morbidity of extensive axillary surgery and has been shown to be feasible in clinically node-negative patients with oncologically safe outcomes. In the adjuvant setting, partial breast irradiation has emerged as a valuable means to improve local control rates with limited associated toxicity and acceptable overall cosmesis. Furthermore, results from prospective trials are now available to support the use of chemotherapy in hormone-receptor negative subgroups, which is associated with improvements in long-term, disease-free, and overall survival.
孤立性乳腺癌局部复发的管理较为复杂,需要仔细考虑既往局部治疗方法,以规划未来的多模式治疗。手术管理的选择已从标准的挽救性乳房切除术和腋窝清扫术发展而来,现在包括在某些患者中重复保乳术和腋窝分期。再次尝试前哨淋巴结活检术可能避免广泛腋窝手术的发病率,并且已经在临床上淋巴结阴性的患者中显示出可行的结果,并且具有良好的肿瘤安全性。在辅助治疗中,部分乳房照射已成为一种提高局部控制率的有效方法,其相关毒性有限,整体美容效果可接受。此外,目前已有前瞻性试验的结果支持在激素受体阴性亚组中使用化疗,这与长期、无病和总体生存率的提高相关。